Global Cephalosporin Drugs Market – Insights
Cephalosporin is a large group of antibiotics that belongs to a class known as beta-lactams. Cephalosporin is a wide spectrum bactericidal antibiotic used for the treatment of several bacterial infections. Cephalosporin drugs are available as both branded and generic medicines. Different generations of cephalosporin are used and preferred for different indications. The third-generation is the most prescribed and broad-spectrum antimicrobial agents useful in a variety of clinical situations. Cefotaxime and ceftizoxime have the best gram-positive bactericidal activity of the third-generation cephalosporin. Ceftazidime and cefoperazone are the only third-generation drugs that provide anti-pseudomonal coverage. Ceftriaxone's long half-life allows for once-daily dosing, making ceftriaxone an excellent drug for outpatient antibiotic therapy of community-acquired infections.
The global cephalosporin drugs market size was valued at US$ 14,240.0 million in 2018, and is expected to witness a CAGR of 3.8% over the forecast period (2019 – 2026).
Global Cephalosporin Drugs Market Share (%) Analysis, By Generation, 2018 & 2026
Source: Coherent Market Insights Analysis (2019)
Increasing Drug Approvals and R&D Activities is expected to Drive Growth of the Cephalosporin Drugs Market
Approvals and launch of novel products is expected to be a major factor driving the global cephalosporin drugs market growth over the forecast period. For instance, in June 2019, Merck & Co. announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for the use of ZERBAXA (ceftolozane and tazobactam) for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Increasing research and development activities has spurred growth of the cephalosporin drugs market. For instance, in November 2017, B. Braun Medical Inc. initiated a clinical trial of Cefazolin infusion evaluating the safety of 1 g and 2 g of Cefazolin in pediatric subjects. The study is in phase 4 and is expected to be completed in July 2019. Therefore, increasing research on cephalosporin drugs is expected to create a favorable environment for the cephalosporin drugs market growth over the forecast period.
Global Cephalosporin Drugs Market - Restraints
Increasing cephalosporin drug recalls by regulatory bodies is hampering the cephalosporin drugs market growth. For instance, in August 2014, Caraco Pharmaceutical Laboratories Ltd., a unit of Sun Pharmaceutical Industries Ltd., initiated a recall of multiple lots of Cephalexin capsules from the U.S. market. According to a notification by the U.S. FDA, the recall of 340,553 units of 500 mg and 113,677 units of 250 mg bottles was voluntarily initiated by the company through a letter to the regulator in June 2014 under ‘Class-II’ classification, owing to Current Good Manufacturing Practice (CGMP) deviations.
Global Cephalosporin Drugs Market - Regional Insights
On the basis of region, the global cephalosporin drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global cephalosporin drugs market during the forecast period, owing to increasing number of product launches. For instance, in August 2017, Dr. Reddy’s Laboratories Ltd. launched Cefixime for Oral Suspension, a therapeutic equivalent generic version of Suprax (cefixime) for Oral Suspension, in the U.S. market. The Suprax brand and generic had US sales of approximately US$ 50.5 million for the 12 months ended in June 2017.
Asia Pacific is expected to foresee a rapid growth in the cephalosporin drugs market. The market in Asia Pacific is expected to gain momentum during the forecast period, owing to increasing strategic partnership for distribution of cephalosporin drugs. For instance, in September 2017, Basilea Pharmaceutica Ltd. announced that its subsidiary, Basilea Pharmaceutica International Ltd. (Basilea), entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for Basilea's antibiotic Zevtera (ceftobiprole) in China.
Global Cephalosporin Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026
Source: Coherent Market Insights Analysis (2019)
Key players operating in the global cephalosporin drugs market include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG.
Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization’s (WHO) report of February 2018, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.
Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.
However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section
Table of Contents
*Browse 53 market data tables and 50 figures on "Cephalosporin Drugs Market” - Global forecast to 2026”
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.